Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID‐19

Objective The present study aimed to investigate the in vivo activity of nasal irrigation (NI) with saline, NI with povidone–iodine (PVP–I) 1%, NI with a mix of hypertonic alkaline and PVP–I 1% against Severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2). Design This study was a prospective...

Full description

Saved in:
Bibliographic Details
Published in:Clinical otolaryngology 2023-07, Vol.48 (4), p.623-629
Main Authors: Batioglu‐Karaaltin, Aysegul, Yigit, Ozgur, Cakan, Dogan, Akgul, Ozer, Yigit, Enes, Yilmaz, Yetkin Zeki, Cakir, Kays‐ı Burak, Ciftci, Gamze, Boyoğlu, Nihal Seden, Cagliyan, Abdurrahman, Can, Efe, Dikme, Ozgur, Hacioglu, Yalcin, Balkan, Ilker Inanc, Enver, Ozgur, Ozdogan, Hasan Ahmet
Format: Article
Language:English
Subjects:
Adult
Coronaviruses
COVID-19
COVID-19 Drug Treatment
Health services
Humans
hypertonic alkaline solution
In vivo methods and tests
Iodine
Nasal Lavage
nasopharyngeal viral load
Patients
Polyvinylpyrrolidone
Povidone
Povidone-Iodine - therapeutic use
povidone–iodine
Prospective Studies
Reduction
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Sodium Chloride
Viral diseases
Viral Load
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The present study aimed to investigate the in vivo activity of nasal irrigation (NI) with saline, NI with povidone–iodine (PVP–I) 1%, NI with a mix of hypertonic alkaline and PVP–I 1% against Severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2). Design This study was a prospective randomised clinical trial. Setting A multicenter study involving tertiary care centres. Participants The study included adult outpatients whose qualitative SARS‐CoV‐2 RT‐PCR tests in nasopharyngeal swabs were positive. One hundred twenty patients were divided into four equal groups. Standard COVID‐19 treatment was given to Group 1, NI containing saline was added to patients' treatment in Group 2, NI containing 1% PVP–I solution was added to patients' treatment in Group 3, and NI containing 1% PVP–I solution and the hypertonic alkaline solution was added to patients' treatment in Group 4. Main Outcome Measures On the first day of diagnosis (Day 0), nasopharyngeal swab samples were taken, on the third and fifth days the nasopharyngeal viral load (NVL) reduction in quantitative RT‐PCR test was calculated. Results Between the zeroth to third days and zeroth to fifth days, the NVL reduction was significant in all groups (p 
ISSN:1749-4478
1749-4486
DOI:10.1111/coa.14056